NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it has acquired privately held antibody maker Affinity BioReagents for an undisclosed amount.
Golden, Colo.-based Affinity makes monoclonal and polyclonal antibodies, peptides, proteins, and other reagents. The firm, which offers more than 35,000 reagents, also provides recombinant proteins and custom antibody-production services, said Thermo Fisher.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.